#United States #Charles C. Foti #Kahn Swick & Foti #New Orleans #Kyverna Therapeutics

Kyverna Therapeutics Class Action Alert

Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., has issued a timely reminder for investors in Kyverna Therapeutics, Inc. (NasdaqGS: KYTX) regarding a significant class action lawsuit. Investors who incurred losses exceeding $100,000 have a nearing deadline to file lead plaintiff applications. This deadline is set for February 7, 2025.

The class action lawsuit originated from concerns related to the company's initial public offering (IPO) conducted in February 2024. The class includes shareholders who purchased shares of Kyverna associated with the company’s registration statement. It is critical that these investors understand their rights and the implications of this lawsuit.

Background of the Lawsuit

The central issue in this ongoing case is the assertion that Kyverna Therapeutics and its executives failed to disclose crucial information in their IPO Registration Statement and accompanying Prospectus. These documents are collectively known as the Offering Documents and are intended to provide prospective investors with material information about the company's financial health and product prospects.

According to the allegations laid out in the complaint, the Offering Documents not only lacked certain disclosures but also contained misleading statements regarding the clinical trials of KYV-101, the company's flagship product. The complaint highlights that while the company claimed improvements in certain patient outcomes, it failed to report adverse results from clinical trials, which were known to the company at the time of the offering. As a result, when this crucial data became public, Kyverna's share price plummeted, leading to significant financial harm for investors.

What Investors Can Do

Investors who purchased shares of Kyverna Therapeutics are encouraged to reach out to KSF Managing Partner Lewis Kahn at 1-877-515-1850 or via email at [email protected] for a no-cost consultation regarding their legal rights and this class action lawsuit. It is essential to act quickly if you wish to serve as a lead plaintiff, as you must file your petition by the specified deadline.

About Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC is recognized as one of the premier boutique securities litigation firms in the United States. With a seasoned team, including former Attorney General Charles C. Foti, Jr., KSF specializes in aiding a diverse array of clients—with a focus on retail investors, institutional investors, hedge funds, and investment managers—to recover losses resulting from corporate misconduct or fraudulent practices by publicly traded companies.

The firm operates in various locations, including New York, Delaware, California, Chicago, Louisiana, and New Jersey. Those wishing to learn more about KSF and its approach to securities litigation can visit www.ksfcounsel.com.

Contact Information:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
Phone: 1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

This alert serves as a crucial reminder for investors to evaluate their positions and consider participation in the lawsuit before the impending deadline. The pursuit of legal action could represent a significant opportunity for recovery against the backdrop of corporate misrepresentation.

Conclusion
As the date approaches, investors affected by Kyverna Therapeutics’ IPO should not delay in exploring their legal options. The repercussions of the alleged misconduct could be substantial, and acting swiftly can make a difference in the outcome of this significant class action lawsuit against the company.